High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 41-45

  Hoogerbrugge, N ^a   Bult, P ^a   De Widt Levert, L M ^a   Beex, L V ^a   Kiemeney, L A ^a   Ligtenberg, M J L ^a   Massuger, L F ^a   Boetes, C ^a   Manders, P ^a   Brunner, H G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST TUMOR; CARCINOMA IN SITU; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERPLASIA; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PRECANCER; PREVALENCE; PROSPECTIVE STUDY; RISK; ROC CURVE;

ADULT; AGE DISTRIBUTION; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPLASIA; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRECANCEROUS CONDITIONS; PREVALENCE; PROSPECTIVE STUDIES; RISK; ROC CURVE;

EID: 18744377172     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.137     Document Type: Article

References (35)

1. Klijn JG, Janin N, Cortes-Funes H, et al: Should prophylactic surgery be used in women with a high risk for breast cancer? Eur J Cancer 33:2149-2159, 1997.
2. Eisen A, Weber BL: Prophylactic mastectomy-the price of fear. N Engl J Med 340:137-138, 1999.
3. Fentiman IS: Prophylactic mastectomy: Deliverance or delusion. Br J Med 317:1402-1403, 1998.
4. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997.
5. Schrag D, Kuntz KM, Garber JE, et al: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617-624, 2000.
6. Frost MH, Schaid DJ, Sellers TA, et al: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324, 2000.
7. Hughes KS, Papa MZ, Whitney T, et al: Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer 86:1682-1696, 1999.
8. Hartmann LC, Schaid DJ, Woods JE, et al: Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340:77-84, 1999.
9. Meijers-Heijboer H, van Geel B, van Putten WLJ, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001.
10. Narod SA: Hormonal prevention of hereditary breast cancer. Ann N Y Acad Sci 952:36-43, 2001.
11. King MC, Wieand S, Jale K, et al: National Breast and Bowel Project NSABP-P breast cancer prevention trial. JAMA 286:2251-2256, 2001.
12. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002.
13. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998.
14. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73:643- 651, 1994.
15. Egan RL: Multicentric breast carcinomas: Clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer 49:1123-1130, 1982.
16. Holland R, Veiling SH, Mravunac M, et al: Pathologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breastconserving surgery. Cancer 56:979-990, 1985.
17. Page DL, Dupont WD, Rogers LW, et al: Atypical hyperplastic lesions of the female breast. A long term follow-up study. Cancer 55:2698- 2708, 1985.
18. Page DL, Rogers LW: Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23:1095- 1097, 1992.
19. Holland R, Peterse JL, Millis RR, et al: Ductal carcinoma-in-situ: A proposal for a new classification. Semin Diagn Path 11:167-180, 1994.
20. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorecctomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999.
21. Turner BC, Harrold E, Matloff E, et al: BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implication for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017-3024, 1999.
22. Frykberg ER, Bland KI: In situ breast carcinoma. Adv Surg 26:29-72, 1993.
23. Khurana KK, Loosmann A, Numann PJ, et al: Prophylactic mastectomy. Pathologic findings in high-risk patients. Arch Pathol Lab Med 124:378-381, 2000.
24. Karabela-Bouropoullou V, Liapi-Avgeri G, Iliopoulou E, et al: Histological findings in breast tissue specimens from reduction mammoplasties. Pathol Res Pract 190:792-798, 1994.
25. Alpers CE, Wellings SR: The prevalence of carcinoma-in-situ in normal and cancer associated breasts: Hum Pathol 16:796-807, 1985.
26. Ringberg A, Palmer B, Linell F, et al: Bilateral and multifocal breast carcinoma: A clinical and autopsy study with special emphasis on carcinoma- in-situ. Eur J Surg Cancer 17:20-29, 1991.
27. Roubidoux MA, Helvie MA, Wilson TE, et al: Women with breast cancer: Histologic findings in the contralateral breast. Radiology 203:691-694, 1997.
28. Osborne MP, Borgen PI: Atypical ductal and lobular hyperplasia and breast cancer risk. Surg Oncol Clin N Am 2:1-11, 1993.
29. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151, 1985.
30. Abner AA, Connolly JL, Recht A, et al: The relation between the presence and extent of lobular carcinoma-in-situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 88:1072-1077, 2000.
31. Singletary SE: Lobular carcinoma-in-situ of the breast: 31 year experience at the University of Texas M.D. Anderson Cancer Center. Breast Dis 7:157-163, 1994.
32. Hutter RV: The management of patients with lobular carcinoma-insitu of the breast. Cancer 53:798-802, 1984.
33. Rosen PP, Braun DW, Kinne DW: The clinical significance of pre-invasive breast carcinoma. Cancer 46:35-51, 1980.
34. Easton DF, Ford D, Bishop DT: The Breast Cancer Linkage Consortium. Breast and ovarian incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265-271, 1995.
35. Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Contralateral breast cancer risk is influenced by the age of onset in BRCA1-associated breast cancer. Br J Cancer 83:384-386, 2000.